100 related articles for article (PubMed ID: 31242488)
21. REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset.
Yamashita T; Kudo M; Ikeda K; Izumi N; Tateishi R; Ikeda M; Aikata H; Kawaguchi Y; Wada Y; Numata K; Inaba Y; Kuromatsu R; Kobayashi M; Okusaka T; Tamai T; Kitamura C; Saito K; Haruna K; Okita K; Kumada H
J Gastroenterol; 2020 Jan; 55(1):113-122. PubMed ID: 31720835
[TBL] [Abstract][Full Text] [Related]
22. Safety and Efficacy of Lenvatinib Treatment in Child-Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis.
Ogushi K; Chuma M; Uojima H; Hidaka H; Numata K; Kobayashi S; Hirose S; Hattori N; Fujikawa T; Nakazawa T; Wada N; Iwasaki S; Fukushima T; Sano Y; Ueno M; Kawano K; Tsuruya K; Shomura M; Watanabe T; Matsunaga K; Kunishi Y; Saigusa Y; Irie K; Iwabuchi S; Kako M; Morimoto M; Kagawa T; Tanaka K; Maeda S
Clin Exp Gastroenterol; 2020; 13():385-396. PubMed ID: 33061517
[TBL] [Abstract][Full Text] [Related]
23. Comparative analysis of liver functional reserve during lenvatinib and sorafenib for advanced hepatocellular carcinoma.
Terashima T; Yamashita T; Takata N; Toyama T; Shimakami T; Takatori H; Arai K; Kawaguchi K; Kitamura K; Yamashita T; Sakai Y; Mizukoshi E; Honda M; Kaneko S
Hepatol Res; 2020 Jul; 50(7):871-884. PubMed ID: 32307874
[TBL] [Abstract][Full Text] [Related]
24. Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma.
Hiraoka A; Kumada T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Imai M; Joko K; Koizumi Y; Hiasa Y; Michitaka K;
Oncology; 2019; 97(6):334-340. PubMed ID: 31466068
[TBL] [Abstract][Full Text] [Related]
25. Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis.
Kawamura Y; Kobayashi M; Shindoh J; Kobayashi Y; Kasuya K; Sano T; Fujiyama S; Hosaka T; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Ikeda K; Arase Y; Hashimoto M; Kumada H
Liver Cancer; 2020 Jun; 9(3):275-292. PubMed ID: 32647631
[TBL] [Abstract][Full Text] [Related]
26. Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting.
Sho T; Suda G; Ogawa K; Kimura M; Shimazaki T; Maehara O; Shigesawa T; Suzuki K; Nakamura A; Ohara M; Umemura M; Kawagishi N; Natsuizaka M; Nakai M; Morikawa K; Furuya K; Baba M; Yamamoto Y; Kobayashi T; Meguro T; Saga A; Miyagishima T; Yokoo H; Kamiyama T; Taketomi A; Sakamoto N
JGH Open; 2020 Feb; 4(1):54-60. PubMed ID: 32055698
[TBL] [Abstract][Full Text] [Related]
27.
Kawamura Y; Kobayashi M; Shindoh J; Kobayashi Y; Kasuya K; Sano T; Fujiyama S; Hosaka T; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Ikeda K; Arase Y; Hashimoto M; Kumada H
Liver Cancer; 2020 Jan; 9(1):84-92. PubMed ID: 32071912
[TBL] [Abstract][Full Text] [Related]
28. Impact of Adverse Events on the Progression-Free Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study.
Ohki T; Sato K; Kondo M; Goto E; Sato T; Kondo Y; Akamatsu M; Sato S; Yoshida H; Koike Y; Obi S
Drugs Real World Outcomes; 2020 Jun; 7(2):141-149. PubMed ID: 32048238
[TBL] [Abstract][Full Text] [Related]
29. Three criteria for radiological response on survival in patients with hepatocellular carcinoma treated with lenvatinib.
Kaneko S; Tsuchiya K; Kurosaki M; Kirino S; Inada K; Yamashita K; Osawa L; Hayakawa Y; Sekiguchi S; Watakabe K; Okada M; Wang W; Shimizu T; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Takeguchi T; Takeguchi Y; Nakanishi H; Itakura J; Takahashi Y; Himeno Y; Izumi N
Hepatol Res; 2020 Jan; 50(1):137-143. PubMed ID: 31349377
[TBL] [Abstract][Full Text] [Related]
30. Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD-1/PD-L1 Checkpoint Blockade.
Aoki T; Kudo M; Ueshima K; Morita M; Chishina H; Takita M; Hagiwara S; Ida H; Minami Y; Tsurusaki M; Nishida N
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33092011
[TBL] [Abstract][Full Text] [Related]
31. Factors Raising Serum Ammonia Level During Lenvatinib Treatment of Patients With Hepatocellular Carcinoma.
Narita R; Kotoh K; Yoneda A; Motomura M; Harada M
Anticancer Res; 2020 Sep; 40(9):5271-5276. PubMed ID: 32878816
[TBL] [Abstract][Full Text] [Related]
32. Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib.
Ono A; Aikata H; Yamauchi M; Kodama K; Ohishi W; Kishi T; Ohya K; Teraoka Y; Osawa M; Fujino H; Nakahara T; Murakami E; Miki D; Kawaoka T; Abe-Chayama H; Zhang P; Liu S; Makokha GN; Tsuge M; Imamura M; Hayes CN; Chayama K
Ther Adv Med Oncol; 2020; 12():1758835920922051. PubMed ID: 32547646
[TBL] [Abstract][Full Text] [Related]
33. Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis.
Kim JJ; McFarlane T; Tully S; Wong WWL
Oncologist; 2020 Mar; 25(3):e512-e519. PubMed ID: 32162815
[TBL] [Abstract][Full Text] [Related]
34. Favorable radiological antitumor response at 2 weeks after starting lenvatinib for patients with advanced hepatocellular carcinoma.
Kuzuya T; Ishigami M; Ito T; Ishizu Y; Honda T; Ishikawa T; Fujishiro M
Hepatol Res; 2020 Mar; 50(3):374-381. PubMed ID: 31721363
[TBL] [Abstract][Full Text] [Related]
35. Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study.
Ueshima K; Nishida N; Hagiwara S; Aoki T; Minami T; Chishina H; Takita M; Minami Y; Ida H; Takenaka M; Sakurai T; Watanabe T; Morita M; Ogawa C; Hiraoka A; Johnson P; Kudo M
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31284682
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Impact of Surgical Intervention After Lenvatinib Treatment for Advanced Hepatocellular Carcinoma.
Shindoh J; Kawamura Y; Kobayashi Y; Kobayashi M; Akuta N; Okubo S; Suzuki Y; Hashimoto M
Ann Surg Oncol; 2021 Nov; 28(12):7663-7672. PubMed ID: 33904001
[TBL] [Abstract][Full Text] [Related]
37. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Finn RS; Qin S; Ikeda M; Galle PR; Ducreux M; Kim TY; Kudo M; Breder V; Merle P; Kaseb AO; Li D; Verret W; Xu DZ; Hernandez S; Liu J; Huang C; Mulla S; Wang Y; Lim HY; Zhu AX; Cheng AL;
N Engl J Med; 2020 May; 382(20):1894-1905. PubMed ID: 32402160
[TBL] [Abstract][Full Text] [Related]
38. Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma.
Takahashi A; Moriguchi M; Seko Y; Ishikawa H; Yo T; Kimura H; Fujii H; Shima T; Mitsumoto Y; Ishiba H; Takashima H; Nagao Y; Jo M; Arai M; Hara T; Okajima A; Muramatsu A; Morita A; Yoshinami N; Nakajima T; Mitsuyoshi H; Umemura A; Nishikawa T; Yamaguchi K; Itoh Y
Anticancer Res; 2019 Sep; 39(9):5149-5156. PubMed ID: 31519627
[TBL] [Abstract][Full Text] [Related]
39. Dose Intensity/Body Surface Area Ratio is a Novel Marker Useful for Predicting Response to Lenvatinib against Hepatocellular Carcinoma.
Eso Y; Nakano S; Mishima M; Arasawa S; Iguchi E; Nakamura F; Takeda H; Takai A; Takahashi K; Taura K; Seno H
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31877859
[TBL] [Abstract][Full Text] [Related]
40. Response to Lenvatinib Is Associated with Optimal RelativeDose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings.
Sasaki R; Fukushima M; Haraguchi M; Miuma S; Miyaaki H; Hidaka M; Eguchi S; Matsuo S; Tajima K; Matsuzaki T; Hashimoto S; Ooba K; Kugiyama Y; Yatsuhashi H; Motoyoshi Y; Shigeno M; Kinoshita N; Nakao K
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31717674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
